drugset / Trial / NCT04339062
Cemiplimab in AlloSCT/SOT Recipients With CSCC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney transplant. \- This research study involves the following drug(s): * Cemiplimab * Everolimus or Sirolimus * Prednisone
Timeline
- Start
- 2020-11-03
- Primary completion
- 2023-06-12
- Completion
- 2025-03-01
Publications
- Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, Tchekmedyian V, Ruiz ES, Waldman AH, Schmults CD, Riella LV, Lizotte P, Paweletz CP, Chandraker AK, Murakami N, Silk AW. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. J Clin Oncol. 2024 Mar 20;42(9):1021-1030. doi: 10.1200/JCO.23.01498. Epub 2024 Jan 22.
- Bonilla M, Gudsoorkar P, Wanchoo R, Herrmann SM, Jhaveri KD. Onconephrology 2022: An Update. Kidney360. 2023 Feb 1;4(2):258-271. doi: 10.34067/KID.0001582022. Epub 2022 Dec 9.
- Paoluzzi L, Ow TJ. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp. Curr Oncol. 2021 Jan 19;28(1):574-580. doi: 10.3390/curroncol28010057.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Background | Everolimus | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | 10 mg | Oral |
| Background | Sirolimus | Small molecule | — | — |